Suppliers / Nantong Chanyoo Pharmatech

Nantong Chanyoo Pharmatech

China Updated 9 July 2026

Nantong Chanyoo Pharmatech is an API manufacturer based in China. Its GMP standing is certified by MFDS (Korea) and US FDA. Its most recent recorded inspection, by US FDA, closed on 16 May 2025 as NAI.

0
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 16 May 2025 NAI US FDA
  • 22 March 2019 VAI US FDA
  • 18 September 2015 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3011243688

What they file, and where

Molecule Regulators Docs
Ezetimibe SFDA (Saudi Arabia) 1
Rosuvastatin SFDA (Saudi Arabia) 1
Sofosbuvir SFDA (Saudi Arabia) 1
Ticagrelor SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Ezetimibe API Sofosbuvir API Rosuvastatin API Ticagrelor API

Filings and GMP by regulator

Regulator Filings GMP certificates
MFDS (Korea) None 2
US FDA None 1

Questions about Nantong Chanyoo Pharmatech

Is Nantong Chanyoo Pharmatech FDA-registered?
One site operated by Nantong Chanyoo Pharmatech carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Nantong Chanyoo Pharmatech's last inspection go?
The most recent inspection on record closed on 16 May 2025 as NAI (No Action Indicated: nothing objectionable was found). 3 inspections are on file.
Where does Nantong Chanyoo Pharmatech manufacture?
1 registered site is on record, in China (China). Every site is listed on this page with the register it came from.
What does Nantong Chanyoo Pharmatech make?
4 molecules are on record against Nantong Chanyoo Pharmatech, including Ezetimibe, Rosuvastatin, Sofosbuvir and Ticagrelor. Each links through to that molecule's full manufacturer list.
Which regulators recognise Nantong Chanyoo Pharmatech's GMP?
Current GMP certificates are on record from MFDS (Korea) and US FDA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Nantong Chanyoo Pharmatech comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 16 May 2025.

Comparable suppliers

Matrix Pharmacorp shares 2 molecules Changzhou Pharmaceutical Factory shares 2 molecules MSN Laboratories shares 1 molecule Apitoria Pharma shares 1 molecule Hetero shares 1 molecule

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates